Christophe Parsy

As Business & Strategic Development Director at Oxeltis, I combine deep scientific insight with strategic vision to build strong partnerships, identify growth opportunities, and position the company as a key partner in early-stage drug discovery and medicinal chemistry services. Oxeltis is a Montpellier-based CRO focused on delivering high-quality design and synthesis solutions across small molecules, targeted protein degradation, complex nucleoside/nucleotide chemistry and more.

With over 25 years in the pharmaceutical industry — spanning CROs, biotech and large pharma — I bring a proven track record of advancing discovery programs into the clinic, especially in antivirals, oncology and anti-infectives. I previously led the Medicinal Chemistry department and Integrated Drug Discovery Services at Oncodesign Services, where I drove preclinical project delivery, strategic alliances, and international collaborations.

My expertise covers small molecules, prodrugs, DNA-encoded libraries, AI-assisted design, fragment-based drug discovery, and targeted protein degradation. I’m also an author and co-inventor of multiple patents and peer-reviewed publications, reflecting a consistent commitment to scientific innovation and excellence.

With an Executive MBA and training in Lean Six Sigma, Strategy and Leadership, I bridge technical and commercial perspectives — enabling effective team leadership and business growth in complex drug discovery environments.